Cargando…

5559749 A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR

Detalles Bibliográficos
Autores principales:	Andemariam, B., Idowu, M., Shah, N., Drachtman, R., Sharma, A., Glaros, A., Achebe, M., Nero, A., Curtis, S., Minniti, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112496/ http://dx.doi.org/10.1097/01.HS9.0000928156.81241.2c

Ejemplares similares

P1485: A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR
por: Andemariam, B., et al.
Publicado: (2022)

P1432: PATTERNS OF VOXELOTOR USE IN A MULTICENTER, REAL-WORLD STUDY OF PATIENTS WITH SICKLE CELL DISEASE
por: Andemariam, Biree, et al.
Publicado: (2023)

PB2516: ACTIGRAPHY IMPROVEMENT WITH VOXELOTOR (ACTIVE) STUDY: IMPACT OF VOXELOTOR ON PHYSICAL ACTIVITY, FATIGUE, AND SLEEP QUALITY
por: Shah, Nirmish, et al.
Publicado: (2023)

5579775 OVERVIEW OF THE VOXELOTOR POST-APPROVAL CLINICAL RESEARCH PROGRAM
por: Minniti, C., et al.
Publicado: (2023)

Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor
por: Glaros, Alexander K., et al.
Publicado: (2021)

S118: LONG-TERM SAFETY AND EFFICACY OF VOXELOTOR FOR PATIENTS WITH SICKLE CELL DISEASE: RESULTS FROM AN OPEN-LABEL EXTENSION OF THE PHASE 3 HOPE TRIAL
por: Achebe, M, et al.
Publicado: (2022)

Patient-Reported Experiences in Voxelotor-Treated Children and Adults with Sickle Cell Disease: A Semistructured Interview Study
por: Brown, Clark, et al.
Publicado: (2023)

S131: REGIONAL ASSESSMENT OF THE EXPERIENCES OF HEALTHCARE PROFESSIONALS (HCPS) TREATING PATIENTS WITH SICKLE CELL DISEASE (SCD): THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: Osunkwo, I, et al.
Publicado: (2022)

Patient perception of voxelotor treatment benefit in sickle cell disease
por: Idowu, Modupe, et al.
Publicado: (2022)

Voxelotor Treatment Providing Transfusion Independence for Patient With Combined Sickle Cell Disease and Lipopolysaccharide-Responsive and Beige-Like Anchor (LRBA) Deficiency
por: Larkin, Kelsey M, et al.
Publicado: (2023)

The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease
por: Minniti, Caterina P., et al.
Publicado: (2021)

Voxelotor: A Ray of Hope for Sickle Disease
por: AlDallal, Salma M
Publicado: (2020)

S279: EFFECT OF VOXELOTOR ON CEREBRAL PERFUSION AND CEREBRAL OXYGEN METABOLISM IN ADULT PATIENTS WITH SICKLE CELL DISEASE; THE COVERAGE STUDY
por: Konté, Kadère, et al.
Publicado: (2023)

5610357 REDUCTION IN BLOOD TRANSFUSION BURDEN FOLLOWING INITIATION OF VOXELOTOR OR CRIZANLIZUMAB: A CASE SERIES
por: Baruwa Etti, A., et al.
Publicado: (2023)

Practical Guidance for the Use of Voxelotor in the Management of Sickle Cell Disease
por: Barriteau, Christina M, et al.
Publicado: (2022)

5610417 IN-VITRO REAL-TIME OBSERVATION OF MODERATE SICKLING KINETICS IN SICKLE ERYTHROCYTES TREATED BY VOXELOTOR UNDER MONOTONIC AND CYCLIC HYPOXIA
por: Qiang, Y.Q., et al.
Publicado: (2023)

P-059: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 3 RESOLVE TRIAL INVESTIGATING THE EFFICACY OF VOXELOTOR WITH STANDARD OF CARE IN THE RESOLUTION OF LEG ULCERS IN PATIENTS WITH SICKLE CELL DISEASE
por: C., MINNITI, et al.
Publicado: (2022)

Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease
por: Yenamandra, Avani, et al.
Publicado: (2020)

P1450: VOXELOTOR TREATMENT LEADS TO IMPROVED VIABILITY OF SICKLE ERYTHROCYTES
por: Konté, Kadère, et al.
Publicado: (2023)

Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high‐ and low‐ to middle‐income countries for the international Sickle Cell World Assessment Survey
por: Osunkwo, Ifeyinwa, et al.
Publicado: (2022)

Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease
por: Telfer, Paul, et al.
Publicado: (2018)

Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe
por: Ferlis, Mica, et al.
Publicado: (2022)

Modeling the public health impact of voxelotor in the management of sickle cell disease in France
por: Galacteros, Frédéric, et al.
Publicado: (2023)

P-010: TREATMENTS FOR SICKLE CELL DISEASE (SCD) AND THE HEALTHCARE PROFESSIONAL (HCP)–PATIENT RELATIONSHIP: HCP OPINIONS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: B., ANDEMARIAM, et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease
por: Hutchaleelaha, Athiwat, et al.
Publicado: (2019)

Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
por: Migotsky, Michael, et al.
Publicado: (2022)

S268: INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)
por: Anderson, Alan, et al.
Publicado: (2023)

More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
por: Langley, Paul C
Publicado: (2020)

P1467: HEALTHCARE PROFESSIONALS (HCP) OPINIONS ON TREATMENTS FOR SICKLE CELL DISEASE (SCD) AND THE HCP–PATIENT RELATIONSHIP: RESULTS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: Andemariam, B., et al.
Publicado: (2022)

More to voxelotor than meets the eye?
por: Bovino, Robert C., et al.
Publicado: (2022)

Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma
por: Savic, Radojka M., et al.
Publicado: (2022)

5613022 SOCIETAL BURDEN OF SICKLE CELL DISEASE IN THE UK: EMPIRICAL ESTIMATES OF PRODUCTIVITY LOSS AND LOSS OF FUTURE INCOME USING REAL-WORLD EVIDENCE
por: Besser, M., et al.
Publicado: (2023)

Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease
por: Alshurafa, Awni, et al.
Publicado: (2022)

Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
por: Preston, Richard A., et al.
Publicado: (2020)

5609968 REAL-WORLD PATIENT-REPORTED OUTCOMES AND WEARABLE METRIC CORRELATIONS: REMOTE DAILY MONITORING FOR EXPLORATION OF QUALITY OF LIFE IN SICKLE CELL DISEASE
por: Agrippa, O.A., et al.
Publicado: (2023)

Voxelotor versus other therapeutic options for sickle cell disease: Are we still lagging behind in treating the disease?
por: Tayyaba Rehan, Syeda, et al.
Publicado: (2022)

Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY)
por: Osunkwo, Ifeyinwa, et al.
Publicado: (2021)

Model‐informed drug development of voxelotor in sickle cell disease: Exposure‐response analysis to support dosing and confirm mechanism of action
por: Green, Michelle L., et al.
Publicado: (2022)

Voxelotor Modulates the Analgesic Effect of Certain Opioids
por: Ballas, Samir K.
Publicado: (2021)

P-013: VOXELOTOR REDUCES SICKLE RED BLOOD CELL-MEDIATED HYPOXIC MICROVASCULAR OCCLUSION AS MEASURED BY OCCLUSIONCHIP IN VITRO MICROFLUIDIC ASSAY
por: Z., SEKYONDA, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b3j2r5kceq3fd0r9i3pbovnj8n